Indomethacin 5-fluorouracil methyl ester pharmaceutical compound and its formulation and preparation method

A technology of methyl fluorouracil and indomethacin, applied in the field of medicine, can solve the problems of high toxicity, restricted use and the like

Inactive Publication Date: 2007-05-16
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although IDM and 5-fluorouracil (5-FU) have a certain synergistic effect, t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Indomethacin 5-fluorouracil methyl ester pharmaceutical compound and its formulation and preparation method
  • Indomethacin 5-fluorouracil methyl ester pharmaceutical compound and its formulation and preparation method
  • Indomethacin 5-fluorouracil methyl ester pharmaceutical compound and its formulation and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Example 1 Synthesis of indomethacin 5-fluorouracil methyl ester

[0011] 1.30g (10mmol) 5-FU and 1.78g (22mmol) formaldehyde aqueous solution (37%) were heated and stirred on a water bath at 60°C until the solids were completely dissolved, then the reaction was continued for 50min, and water and excess formaldehyde were distilled off under reduced pressure to obtain The transparent intermediate product 1,3-dimethylol-5-FU. Add 100 mL of anhydrous acetonitrile, 4.3 g (12 mmol) IDM, 2.47 g (14 mmol) N, N-dicyclohexylcarboimide (DCC), 0.08 g N, N-dimethylaminopyridine (DMAP), room temperature The reaction was stirred for more than 72 hours, and the progress of the reaction was monitored by thin layer chromatography (TLC). After the reaction was completed, the precipitate was removed by filtration, and the filtrate was distilled under reduced pressure to recover acetonitrile. The residue was dissolved in an appropriate amount of ethyl acetate, and washed successively with ...

Embodiment 2

[0017] Example 2 Antitumor activity of indomethacin-5-fluorouracil methyl ester

[0018] mouse sarcoma S 180 Tumor strain, liver cancer H 22 Tumor strains and three tumor strains of Lewis lung cancer solid tumors were used as indicators to investigate the anti-tumor activity of IFM.

[0019] In vitro resuscitation of mouse sarcoma S 180 Tumor strain, liver cancer H 22 Tumor strain and Lewis lung cancer tumor strain, cells were collected during the exponential growth phase of the cells, 1000r·min -1 Centrifuged, washed twice with PBS, sucked off the supernatant, diluted with sterile saline, adjusted to 2×10 7 pcs mL -1 . Randomly select healthy mice, inject 0.2mL of the above cell suspension into the intraperitoneal cavity, and observe the growth of the ascites of the inoculated mice. About a week after the inoculation, the abdomen of the inoculated mice is obviously enlarged and protruding, and the ascites is extracted. In a sterile test tube, dilute it with sterile sal...

Embodiment 3

[0026] Example 3 Acute toxicity of indomethacin-5-fluorouracil methyl ester.

[0027] Accurately weigh an appropriate amount of medicine, dissolve it with 1% CMC-Na to 15mL, take 6mL as the first group of medicine, dilute the remaining medicine to 15mL, take 6mL as the second group of administration, and so on. 50 mice were evenly divided into 5 groups according to sex and body weight, 10 mice in each group, and administered intragastrically according to the designed dosage, and the administration volume was 20mL / kg. Observed for 14 days after administration. The death of animals in each group was recorded. There were no obvious lesions in the major organs of the mice in the autopsy.

[0028] Bliss method calculation, 5-FU, IDM, 5-FU and IDM physical mixture 1:1 (mol / mol) and IFM half lethal dose (LD 50 ) are 82.28mg / kg, 260.09mg / kg, 200.34mg / kg and 1929.57mg / kg respectively.

[0029] The results showed that compared with the two original drugs and the physical mixture of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new compound indomethacin 5-efudix methyl ester and agent and preparing method, whose chemical names is 1-(4-chlorobenzene formyl)-5-methoxyl-2-methyl indole-3-acetate (5-fluorine-3, 4-dihydrogen-2, 4-dioxo-1 (2H)-pyrimidinyl) methyl ester, wherein the compound is reacted by 5-FU and formaldehyde to produce intermediate 1,3-dimethylol-5-FU, which combines IDM to form the product as tablet or capsule with acceptable medical carrier or excipient.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, and discloses a medicinal compound of indomethacin 5-fluorouracil methyl ester, a preparation and a preparation method thereof. Background technique: [0002] The relationship between inflammation and cancer has attracted people's attention very early. Professor Ji Zhizhong of Shenyang Pharmaceutical University published an article entitled "Cancer and Inflammation and New Drug Research" as early as 1986. It is pointed out that indomethacin (IDM) can inhibit the synthesis of PGs in cell proliferation on the one hand, and on the other hand, it can inhibit tumor growth due to the increase of lipoxygenase production and other effects of indomethacin (such as anti-inflammatory effect) contribute to anti-inflammatory effects. cancer effect. Because inflammation can promote tumor formation and growth. On November 16, 2004, Health Net pointed out in the article "Scientists' Latest Research Reveals t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D403/12A61K31/506A61P35/00A61P29/00
Inventor 王晶张向荣张莹王岩周晓棉莫凤奎
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products